Clinical trials
Medullary Thyroid Cancer clinical trials
Below are recruiting medullary thyroid cancer clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05088187Recruiting
Study of thinking and quality of life after thyroid surgery
This study looks at how thyroid surgery affects thinking (cognition) and day-to-day quality of life. It may help patients and doctors understand what to expect and how to support people after surgery.
StockholmAges 18 years+ - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06482086RecruitingPhase 2
Using tumor models to guide drug choice for advanced thyroid cancer
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Chengdu, SichuanAges 18 years+ - NCT06860971RecruitingPhase 3
AL2846 capsule vs placebo for advanced thyroid cancer
This study tests a new oral capsule (AL2846) against a placebo in people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if AL2846 can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT06286631Recruiting
Predicting lymph node spread in thyroid cancer with a new scale
This trial is testing a new scale to predict if thyroid cancer has spread to nearby lymph nodes. It may help doctors decide on the best treatment for you.
Xi'an, ShaanxiAges 16–80 - NCT07383246RecruitingPhase 3
FAPI-guided surgery for newly diagnosed medullary thyroid cancer
This trial tests whether a special imaging agent (FAPI) can help surgeons remove medullary thyroid cancer more precisely during your first surgery. It is for people who have not yet been treated and are scheduled for surgery within 30 days.
Beijing, Beijing MunicipalityAges Any age - NCT06855680Recruiting
EMIRATES: Observing low-risk thyroid cancer without completion surgery
This study tests whether it is safe to monitor small, low-risk thyroid cancers (1–4 cm) instead of removing the remaining thyroid tissue after initial surgery. It may help you avoid a second operation and lifelong medication if your cancer is truly low-risk.
WiganAges 18 years+ - NCT04290663RecruitingPhase 3
Radioiodine decision after thyroid surgery for intermediate-risk cancer
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
Pointe à Pitre, GuadeloupeAges 18 years+ - NCT07138716Recruiting
PET/CT scan for medullary thyroid carcinoma
This study tests a new imaging agent (68Ga-DOTA-CCK-FS) that helps doctors see medullary thyroid carcinoma (MTC) and other tumors with CCK-2 receptors using a PET/CT scan. It may help find or monitor these tumors more clearly.
Beijing, Beijing MunicipalityAges Any age - NCT07235566RecruitingPhase 2
MRG003 plus pucotenlimab for advanced thyroid cancer (ATC/PDTC)
This trial tests two drugs together: MRG003 (a targeted therapy that delivers chemo directly to EGFR-positive cancer cells) and pucotenlimab (an immunotherapy that helps your immune system attack the cancer). It is for people with a rare and aggressive thyroid cancer (ATC or PDTC) whose tumors have the EGFR protein and have grown despite previous treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+
Hear when a new Medullary Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for medullary thyroid cancer?
- Yes. Clin2 currently lists 35 recruiting medullary thyroid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a medullary thyroid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a medullary thyroid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.